Previous 10 | Next 10 |
PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +25% on out-licenses sarcopenia candidate PB1023. More news on: PhaseBio Pharmaceuticals, Inc., Cerner Corporation, SCYNEXIS, Inc., Stocks on the move, Read more ...
SCYNEXIS (NASDAQ: SCYX ) +14% on Candida auris and the major global health issues caused by drug-resistant pathogens . More news on: SCYNEXIS, Inc., New Age Beverages Corporation, Genfit SA, Stocks on the move, Read more ...
JERSEY CITY, N.J. , April 8, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today commended the New York Times for its reporting on Candida auris and the ...
With the first quarter of 2019 officially over, the end of each quarter represents an opportune time to reflect on the top performing stocks of each industry — including the pharmaceuticals sector. Throughout Q1 2019, drug pricing remained a constant topic of conversation, even in Con...
JERSEY CITY, N.J. , April 3, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced data demonstrating the potential use of ibrexafungerp as an agent to ...
Scynexis (NASDAQ: SCYX ) is 4.6% lower after hours after a shareholder filing to offer just over 13M shares . More news on: SCYNEXIS, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Noteworthy events during the week of March 17 - 23 for healthcare investors. More news on: SCYNEXIS, Inc., Sage Therapeutics, Inc., Intrexon Corporation, Healthcare stocks news, , Read more ...
SCYNEXIS (NASDAQ: SCYX ): FY GAAP EPS of -$0.28. More news on: SCYNEXIS, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
JERSEY CITY, N.J. , March 14, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the year ended December 31, 2018 , and provide...
JERSEY CITY, N.J. , March 7, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the sale of a $16.0 million aggregate principal amount of 6.0% conve...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...